# The Use of VSL#3 in Irritable Bowel Syndrome in Children

> **NCT00932841** · PHASE1 · TERMINATED · sponsor: **Dayton Children's Hospital** · enrollment: 15 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **OTHER:** Placebo
- **DRUG:** VSL#3 900 billion bacteria
- **DRUG:** VSL#3 90 billion bacteria

## Key facts

- **NCT ID:** NCT00932841
- **Lead sponsor:** Dayton Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** PI has re-located. PI terminated FDA IND # and closed study.
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932841, "The Use of VSL#3 in Irritable Bowel Syndrome in Children". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00932841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*